



Express Mail No.: <u>EV 003 684 794 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Langermann et al.

Confirmation No. 9514

Application No.: 10/015,085

Group Art Unit: 1645

#7 /K.1. 10/23 T.D.S.

Filed: December 10, 2001

Examiner: To Be Assigned

For:

MUTANT PROTEINS, HIGH POTENCY

Attorney Docket No.: 10271-037-999

INHIBITORY ANTIBODIES AND FIMCH

CRYSTAL STRUCTURE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

RECEIVED

Assistant Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicants or Attorneys for Applicants which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-BS listed on the attached revised form PTO 1449. A copy of each of the identified references is enclosed herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited by Applicant" instead of "List of Prior Art Cited."

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449 and make them of record in the file history of the aboveidentified application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is believed to be filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP deposit account no. 16-1150; a duplicate of this sheet is enclosed.

Respectfully submitted,

Date June 19, 2002

Un thony M. Insom 35,203

(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N.Y. 10036-2711 (212) 790-9090

Enclosure

By Margaret B. Porivar RegNo. 40,922


RECEIVED

Expr ss Mail No. EV 003 684 794 US

JUN 2 4 2002

JUN 1 9 2002 TECH CENTER 1600/2000 -037-999 APPLICATION NO. TRADEMA 10/015,085 IST OF REFERENCES CITED BY APPLICANT APPLICANT CONFIRMATION NO. (Use several sheets if necessary) Langermann et al. 9514 FILING DATE GROUP December 10, 2001 1645 **U.S. PATENT DOCUMENTS** *EXAMINER INITIAL DOCUMENT NUMBER DATE CLASS SUBCLASS APPROPRIATE AA 11/21/89 4.882,425 Hull et al. AB 4,971,794 11/20/90 Linggood et al. AC 09/298,494 04/23/99 Langermann et al. <u> JÜN</u> ΑD 07/07/00 60/216,750 Langermann et al. 1800 | 2900 ΑE 09/615,846 07/13/00 Hultgren et al. AF 09/616,702 07/14/00 Hultgren et al. AG 6,103,243 08/15/00 Russell-Jones et al. **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER DATE SUBCLASS TRANSLATION YES NO AΗ WO 95/14028 05/26/95 PCT ΑI WO 95/20657 08/03/95 **PCT** AJ WO 01/04148 01/18/01 PCT AK WO 01/10386 02/15/01 PCT OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) Abraham et al., 1985, "Protection against Escherichia coli-induced urinary tract infections with Hybridoma antibodies directed against type I Fimbriae of complementary D-mannose receptors" AL Infect. and Immunity 48: 625-628 Chapman et al., 1999, "Structural and functional significance of the FGL sequence of the periplasmic AM chaperone Caf1M of Yersinia pestis" J. Bacteriol. 181(8):2422-2429 Choudhury et al., 1999, "X-ray structure of the FimC-FimH chaperone-adhesin complex from AN uropathogenic Escherichia coli" Science 285(5430):1061-6 Dodson et al., 1993, "Outer-membrane PapC molecular usher discriminately recognizes periplasmic AO chaperone-pilus subunit complexes" PNAS 90:3670-3674 Flemmer et al., 1995, "Peptides inhibit complexation of the bacterial chaperone PapD and reveal ΑP potential to block assembly of virulence associated pili" Bioorg. Med. Chem. Lett. 5(9):927-932 Hultgren et al., 1989, "The PapG adhesin of uropathogenic Escherichia coli contains separate regions AQ for receptor binding and for the incorporation into the pilus" PNAS 86(12):4357-61 Hultgren et al., 1990, "Mannose-sensitive haemagglutination in the absence of palliation in AR Escherichia coli" Mol. Microbiol. 4:1311-8 Hung et al., 1996, "Molecular basis of two subfamilies of immunoglobulin-like chaperones" EMBO J. AS 15(15):3792-805 Jones et al., 1993, "FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in AT bacteria" PNAS 90(18):8397-401

	018		s	Sheet 2 of 3
	IN 1 9 2002	C5833	Knight et al., 1997, "Crystalization and preliminary x-ray diffraction studies of the FimC-F chaperone-adhesin complex from Escherichia coli" <i>Acta Cryst</i> . D53:207	imH
V.	DADEMARKO	AV	Langermann et al., 1997, "Prevention of mucosal Escherichia coli infection by FimH-adh systemic vaccination" Science 276(5312):607-11	esin-based
		AW	Langermann et al., 1996, "New approaches to mucosal immunization" Semin Gastrointe. 7(1):12-8	st Dis.
Ω	~~		Langermann et al., 2000, "Vaccination with FimH adhesin protects Cynomolgus monkey colonization and infection by uropathogenic Escherichia coli" <i>J. Infect. Dis.</i> 181(2):774-7	
RECEIVE	7 6	 	Madison et al., 1990, "Structural, Antigenic and Functional Analysis of FimH Protein in Es and Klebsiella pneumoniae Type I Fimbriae: A Dissertation Presented to the Graduate S Council" The University of Tennessee, Memphis.	
	CN	-Az	Montgomery et al., 1997, "DNA vaccines" Pharmacol. Ther. 74(2):195-205	
Œ	-,	E E B A	O'Hanley et al., 1985, "Molecular Basis of escherichia coli colonization of the upper urina BALB/c mice" <i>J. Clin. Invest.</i> 75: 347-60	ry tract in
		вв	Prince et al., 1985, "Immunoprophylaxis and immunotherapy of respiratory syncytial virus the cotton rat" <i>Virus Res.</i> 3:193-206	s infection in
		вс	Prince et al., 1990, "Mechanism of antibody-mediated viral clearance in immunotherapy syncytial virus infection of cotton rats" <i>J. Virol.</i> 64:3091-3092	of respiratory
		BD	Roberts et al., 1994, "The Gal (α1-4) Gal-specific tip adhesin of Escherichia coli P-fimbri for pyelonephritis to occur in the normal urinary tract" <i>PNAS</i> 91: 11889-11893	ae is needed
į		BE	Salit and Gotschlich, 1977, "Type I Escherichia coli pili: characterization of binding to mo cells" <i>J. Exp. Med.</i> 146(5):1182-1194	nkey kidney
		BF	Sauer et al., 1999, "Structural basis of chaperone function and pilus biogenesis" <i>Science</i> 285(5430):1058-61	
		BG	Service et al., 1994, "Triggering the first line of defense" Science 265(5178):1522-4	
		вн	Sokurenko et al. 1995, "Quantitative differences in adhesiveness of type 1 fimbriated Eso due to structural differences in FimH genes" <i>J. Bacteriol.</i> 177:3680-86	cherichia coli
		ВІ	Sokurenko et al., 1997, "Diversity of the Escherichia coli type 1 fimbriae lectin. Differentia mannosides and uroepithelial cells" <i>J. Biol. Chem.</i> 272:17880-6	al binding to
		BJ	Sokurenko et al., 1998, "Pathogenic adaptation of Escherichia coli by natural variation of adhesin" <i>PNAS</i> 95:8922-6	the FimH
		вк	Soto et al., 1998, "Periplasmic chaperone recognition motif of subunits mediates quatern interactions in the pilus" <i>EMBO J.</i> 17(21):6155-6167	ary
		BL	Striker et al., 1994, "Stable fiber-forming and nonfiber-forming chaperone-subunit complebiogenesis" <i>J. Biol. Chem.</i> 269(16):12233-12239	exes in pilus
		вм	Tewari et al., 1993, "Neutrophil Activation by Nascent FimH Subunits of Type 1 Fimbriae from the Perimplasm of Escherichia coli" <i>J. Biol. Chem.</i> 268: 3009-3015	Purified
		BN	Thankavel et al., 1997, "Localization of a domain in the FimH adhesin of Escherichia coli fimbriae capable of receptor recognition and use of a domain-specific antibody to confer against experimental urinary tract infection" <i>J. Clinical Investigation</i> 100:1123-1136	
}		во	Wilson et al., 1984, "The structure of an antigenic determinant in a protein" Cell 37(3):767	7-78
		вР	Wizemann et al., 1999, "Adhesins as targets for vaccine development" <i>Emerg. Infect. Dis</i> 5(3):395-403	
		BQ	Wu and Wu, 1987, "Receptor-mediated in vitro gene transformation by a soluble DNA ca <i>J Biol Chem.</i> 262(10):4429-32	rrier system"



RECEIVED
JUN 6 6 2002
TECH CONTER 1600/2900